BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Eli Lilly and Kumquat Seek Enhanced Tumor-Specific Immune Response in $2B+ Deal

  The two companies announced their exclusive collaboration that will harness Kumquat’s small molecule immuno-oncology platform’s capabilities to discover novel clinical candidates.

  July 29, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  New Day For Diabetes Patients As FDA Approves First-Ever Interchangeable Biosimilar

  Semglee was approved under the FDA’s 351(k) pathway, a biologics license application process. It ensures that the bio similarity is based on animal studies, clinical trials, and analytical studies.

  July 29, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  Pfizer-BioNTech Vaccine: African Deal, $34 Billion in Sales, and Efficacy Drop

  Pfizer has reported several highlights regarding its mRNA COVID-19 vaccine. As the world deal with rising Delta variant cases, Pfizer-BioNTech is still arguing that a third booster shot will be likely.

  July 29, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  New Infusion of Cash For A Trio of Global Biotech And Pharma Firms

  Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.

  July 29, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Future of AstraZeneca’s Vaccine Business is Murky, But Seeks to Move Ahead with FDA Filing

  AstraZeneca said in an earnings announcement on Thursday it will seek authorization for its COVID-19 vaccine in the U.S. sometime in the second half of this year.

  July 29, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Policy

  Kaiser Sues Merck, Generic Drug Firm Over Millions in Losses Due to Alleged “Pay-for-Delay” Scheme

  Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a “pay-for-delay” scheme that cost the former millions of dollars.

  July 29, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Three Biopharma Companies Made Public Debut on Nasdaq Exchange

  Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today.

  July 29, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  COVID News: EUA Expanded for Baricitinib, Emergent Starts to Manufacture J&J Vaccine Again and More

  As COVID-19 infections continue to increase in the U.S., the FDA has expanded the EUA for Eli Lilly’s monoclonal antibody to include treatment with or without remdesivir.

  July 29, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  BioForest

  Research Roundup: Immune Memory Against COVID-19 and More

  Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

  July 29, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  bluebird bio and National Resilience Ink Cell Therapy Strategic Alliance

  bluebird bio and National Resilience signed a strategic alliance around cell therapies. As part of the deal, Resilience is buying bluebird’s manufacturing facility in Research Triangle Park, keeping more than 100 staffers.

  July 29, 2021

   · 

  2 min read

   · 

  Mark Terry